Bemotrizinol API Manufacturers

General Description:

Bemotrizinol, identified by CAS number 187393-00-6, is a notable compound with significant therapeutic applications. Bemotrizinol, or bis-ethylhexyloxyphenol methoxyphenyl triazine, is an organic UV filter found in over-the-counter sunscreen products. It primarily absorbs UV-A rays. Compared to older broad-spectrum chemical agents, bemotrizinol is more more fat soluble (oil soluble in cosmetic oils) to aid in efficacy and broad-spectrum activity . It is claimed to be photostable, which increases its onset of action and its efficiency in providing protection against UV-rays upon topical application . Bemotrizinol is commonly marketed as Tinosorb S and Escalol S.

Indications:

This drug is primarily indicated for: Indicated as an active sunscreen agent. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Bemotrizinol undergoes metabolic processing primarily in: No pharmacokinetic data available. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Bemotrizinol are crucial for its therapeutic efficacy: No pharmacokinetic data available. The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Bemotrizinol is an important consideration for its dosing schedule: No pharmacokinetic data available. This determines the duration of action and helps in formulating effective dosing regimens.

Protein Binding:

Bemotrizinol exhibits a strong affinity for binding with plasma proteins: No pharmacokinetic data available. This property plays a key role in the drug's pharmacokinetics and distribution within the body.

Route of Elimination:

The elimination of Bemotrizinol from the body primarily occurs through: No pharmacokinetic data available. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Bemotrizinol is distributed throughout the body with a volume of distribution of: No pharmacokinetic data available. This metric indicates how extensively the drug permeates into body tissues.

Clearance:

The clearance rate of Bemotrizinol is a critical factor in determining its safe and effective dosage: No pharmacokinetic data available. It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Bemotrizinol exerts its therapeutic effects through: Findings from an immature rat uterotrophic competitive binding assay suggest that bemotrizinol does not display significant binding affinities towards estrogen and androgen receptors _in vitro_, thus lacking intrinsic estrogenic, antiestrogenic, androgenic and antiandrogenic activity . Bemotrizinol minimizes erythema and provides excellent anti-aging effects as well as protectant effects on the skin's antioxidant defense system . In a comparative study of individuals with a history of polymorphic light eruption (PLE) undergoing photoprovocation, treatment of bemotrinizol was effective in preventing the development of PLE . The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Bemotrizinol functions by: By absorbing UV-A and UVB rays ranging from 280 to 400nm, bemotrizinol serves to prevent the formation of free radicals induced by UV radiation . This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Categories:

Bemotrizinol is categorized under the following therapeutic classes: Benzene Derivatives, Sunscreen Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Experimental Properties:

Further physical and chemical characteristics of Bemotrizinol include:

• Water Solubility: Insoluble
• Melting Point: 80.4
• Boiling Point: >400